Literature DB >> 19326177

Comparison of CT, PET, and PET/CT for staging of patients with indolent non-Hodgkin's lymphoma.

Barbara J Fueger1, Kristen Yeom, Johannes Czernin, James W Sayre, Michael E Phelps, Martin S Allen-Auerbach.   

Abstract

PURPOSE: The aim was to investigate the potential impact of positron emission tomography (PET)/computed tomography (CT) as compared to PET and CT on the staging of patients with indolent lymphoma. PROCEDURES: PET/CTs from 45 patients with indolent lymphoma undergoing staging or restaging were studied. Clinical follow-up, additional imaging, and histology served as the gold standard.
RESULTS: PET/CT correctly diagnosed 92 nodal regions as positive for lymphomatous involvement and 458 as disease free vs 68 and 449 for PET and 64 and 459 for CT, respectively. The respective sensitivities, specificities, and accuracies were 99%, 100%, and 99.8% for PET/CT, 68%, 97.5%, and 92.2% for PET, and 70%, 100%, and 94.7% for CT. PET/CT performed significantly better than PET (p < 0.001 for sensitivity, specificity, and accuracy) and CT (p < 0.001 for sensitivity and accuracy). PET/CT also correctly identified significantly more extra-nodal lesions (22) than CT (14) and PET (nine).
CONCLUSIONS: PET/CT provides significantly more accurate information compared to PET and CT for the staging and re-staging of patients with indolent lymphoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19326177      PMCID: PMC2693779          DOI: 10.1007/s11307-009-0200-9

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  35 in total

1.  2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial.

Authors:  I Buchmann; M Reinhardt; K Elsner; D Bunjes; C Altehoefer; J Finke; E Moser; G Glatting; J Kotzerke; C A Guhlmann; H Schirrmeister; S N Reske
Journal:  Cancer       Date:  2001-03-01       Impact factor: 6.860

2.  Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL).

Authors:  G Jerusalem; Y Beguin; F Najjar; R Hustinx; M F Fassotte; P Rigo; G Fillet
Journal:  Ann Oncol       Date:  2001-06       Impact factor: 32.976

3.  PET/CT of the abdomen: optimizing the patient breathing pattern.

Authors:  Gerhard W Goerres; Cyrill Burger; Michael R Schwitter; Thai-Nia H Heidelberg; Burkhardt Seifert; Gustav K von Schulthess
Journal:  Eur Radiol       Date:  2002-06-22       Impact factor: 5.315

4.  Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL).

Authors:  F Najjar; R Hustinx; G Jerusalem; G Fillet; P Rigo
Journal:  Cancer Biother Radiopharm       Date:  2001-08       Impact factor: 3.099

5.  Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma.

Authors:  Robert H Blum; John F Seymour; Andrew Wirth; Michael MacManus; Rodney J Hicks
Journal:  Clin Lymphoma       Date:  2003-06

Review 6.  Positron emission tomography in non-Hodgkin's lymphoma (NHL): relationship between tracer uptake and pathological findings, including preliminary experience in the staging of low-grade NHL.

Authors:  Guy H M Jerusalem; Yves P Beguin
Journal:  Clin Lymphoma       Date:  2002-06

7.  Lung adenocarcinoma with mixed bronchioloalveolar and invasive components: clinicopathological features, subclassification by extent of invasive foci, and immunohistochemical characterization.

Authors:  Hiroshi Terasaki; Toshiro Niki; Yoshihiro Matsuno; Tesshi Yamada; Arafumi Maeshima; Hisao Asamura; Naofumi Hayabuchi; Setsuo Hirohashi
Journal:  Am J Surg Pathol       Date:  2003-07       Impact factor: 6.394

Review 8.  First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma.

Authors:  John D Hainsworth
Journal:  Semin Oncol       Date:  2003-02       Impact factor: 4.929

9.  Immunohistochemical analysis of lung carcinomas with pure or partial bronchioloalveolar differentiation.

Authors:  G Peter Sarantopoulos; Dorina Gui; Peter Shintaku; Longshen Hong; Ya-Ying Wang; Cecilia S Yap; Michael C Fishbein
Journal:  Arch Pathol Lab Med       Date:  2004-04       Impact factor: 5.534

10.  FDG-PET/CT in re-staging of patients with lymphoma.

Authors:  L S Freudenberg; G Antoch; P Schütt; T Beyer; W Jentzen; S P Müller; R Görges; M R Nowrousian; A Bockisch; J F Debatin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-11-26       Impact factor: 9.236

View more
  18 in total

1.  Reproducible research in medical imaging.

Authors:  Kingshuk Roy Choudhury; Ray Gibson
Journal:  Mol Imaging Biol       Date:  2012-08       Impact factor: 3.488

2.  Comparison of CT, PET, and PET/CT for staging of patients with indolent non-hodgkin's lymphoma: statistical errors in Fueger et al. (2009).

Authors:  Larry R White
Journal:  Mol Imaging Biol       Date:  2012-08       Impact factor: 3.488

3.  Differentiation of malignant from benign heart and pericardial lesions using positron emission tomography and computed tomography.

Authors:  Dan Shao; Shu-Xia Wang; Chang-Hong Liang; Qiang Gao
Journal:  J Nucl Cardiol       Date:  2011-06-08       Impact factor: 5.952

4.  Current status of PET/CT in the diagnosis and follow up of lymphomas.

Authors:  Carlos Alberto Buchpiguel
Journal:  Rev Bras Hematol Hemoter       Date:  2011

5.  Computer-assisted quantitative evaluation of therapeutic responses for lymphoma using serial PET/CT imaging.

Authors:  Xin Gao; Zhong Xue; Jiong Xing; Daniel Y Lee; Stephen M Gottschalk; Helen E Heslop; Catherine M Bollard; Stephen T C Wong
Journal:  Acad Radiol       Date:  2010-01-12       Impact factor: 3.173

6.  Evaluation of diagnostic performance of whole-body simultaneous PET/MRI in pediatric lymphoma.

Authors:  Maria Rosana Ponisio; Jonathan McConathy; Richard Laforest; Geetika Khanna
Journal:  Pediatr Radiol       Date:  2016-03-22

7.  Comparison of Bone Marrow Involvement with Bone Marrow Biopsy and PET-CT and Evaluation of Any Effects on Survival in Patients Diagnosed with Hodgkin and Non-Hodgkin Lymphoma.

Authors:  Mesut Göçer; Erdal Kurtoğlu
Journal:  Indian J Hematol Blood Transfus       Date:  2020-05-04       Impact factor: 0.900

8.  FDG-PET/CT in lymphoma.

Authors:  Maria M D'souza; Abhinav Jaimini; Abhishek Bansal; Madhavi Tripathi; Rajnish Sharma; Anupam Mondal; Rajendra Prashad Tripathi
Journal:  Indian J Radiol Imaging       Date:  2013-10

9.  Evaluation of a Fast Protocol for Staging Lymphoma Patients with Integrated PET/MRI.

Authors:  Johannes Grueneisen; Lino Morris Sawicki; Benedikt Michael Schaarschmidt; Saravanabavaan Suntharalingam; Sara von der Ropp; Axel Wetter; Verena Ruhlmann; Harald H Quick; Michael Forsting; Lale Umutlu
Journal:  PLoS One       Date:  2016-06-21       Impact factor: 3.240

10.  The usefulness of (18)F-FDG PET/CT for assessing methotrexate-associated lymphoproliferative disorder (MTX-LPD).

Authors:  Shiro Watanabe; Osamu Manabe; Kenji Hirata; Noriko Oyama-Manabe; Naoya Hattori; Yasuka Kikuchi; Kentaro Kobayashi; Takuya Toyonaga; Nagara Tamaki
Journal:  BMC Cancer       Date:  2016-08-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.